Mont-Saint-Guibert, Belgium, and Tokyo, Japan, May 15, 2018 – Promethera® Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the foundation of a new branch office in Tokyo, Promethera® Biosciences Japan Branch Ltd. Establishing a branch office in Japan marks the starting point for building a strong presence of Promethera® in Japan first, initially focusing on increased Business Development, Investor Relations activities and expansion of its business and products pipeline in Japan, this presence will also address the Asian markets as a second step.
“Today, we took another significant step as a global innovator in the liver disease space and are consistently pursuing our vision and strategy. Adding a local presence in Japan, in addition to our corporate headquarters and growing product development organization in Belgium, our US operations and manufacturing center of excellence in the North Carolina Research Triangle, as well as our newly announced Swiss subsidiary Baliopharm AG represents a key milestone for Promethera® in continuing to establish an international footprint,” commented John Tchelingerian, PhD, President & CEO of Promethera® Biosciences SA.
The Asian markets, and particularly the Japanese one, regard cell therapy positively and represent a special opportunity for Promethera®’s products and corporate development activities. The Company has benefitted from the positive climate in Japan and South Korea in the past and was able to attract a significant set of both strategic and institutional investors from these prominent countries in cell therapies, including Mitsui & Co. Global Investment, Mitsubishi UFJ Capital Co., Ltd., Cell Innovation Partners, L.P., Shibuya Corporation and Shinsei Corporate Investment from Japan, and LifeLiver Co., Ltd. from South Korea. Promethera® is committed to build on these strong initial ties and continue expanding its network in Japan, South Korea and the wider Asian region.